azadine (azacitidine powder for suspension for injection 100mgvial)
accord healthcare sdn.bhd. - azacitidine -
azadual 100 (azacitidine powder for suspension for injection 100mgvial)
mega lifesciences sdn. bhd. - azacitidine -
avoxred (azacitidine) powder for suspension for injection 100 mgvial
dr. reddy`s laboratories malaysia sdn. bhd. - azacitidine -
onureg 200 mg
bristol, myers squibb (israel) limited, israel - azacitidine - film coated tablets - azacitidine 200 mg - azacitidine - onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following intensive induction chemotherapy and are not able to complete intensive curative therapy
onureg 300 mg
bristol, myers squibb (israel) limited, israel - azacitidine - film coated tablets - azacitidine 300 mg - azacitidine - onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following intensive induction chemotherapy and are not able to complete intensive curative therapy
azacitidine ans azacitidine 100 mg powder for injection vial
southern xp ip pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine ans is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),,? chronic myelomonocytic leukaemia [cmmol (10-29 percent marrow blasts without myeloproliferative disorder)],,? acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.
azacitidine lws azacitidine 100 mg powder for injection vial
southern xp ip pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine lws is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),,? chronic myelomonocytic leukaemia [cmmol (10-29 percent marrow blasts without myeloproliferative disorder)],,? acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.
azacitidine sxp azacitidine 100 mg powder for injection vial
southern xp ip pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine sxp is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),,? chronic myelomonocytic leukaemia [cmmol (10-29 percent marrow blasts without myeloproliferative disorder)],,? acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.
azacitidine epsl azacitidine 100 mg powder for injection vial
eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine epsl is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.
azacitidine eugia azacitidine 100 mg powder for injection vial
eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine eugia is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.